Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × SH-1028 × Clear all
NCT06080776 2023-10-12

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 3 Recruiting
242 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04239833 2020-01-27

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 3 Unknown
240 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡